The antitumor and immunomodulatory activity of chemo-imunotherapy regimen based on dendritic cells and low-dose doxorubicin has been investigated in CBA mice with sarcoma-37. We have found that scheme of combination therapy based on DC vaccine and doxorubicin at a dose of 0.2 mg/kg significantly contributes to the reduction of the primary tumor volume in animals with transplanted tumor. Application of this therapeutic regimen enhances the functional activity of the immune system of tumor-bearing animals, in particular phagocytic and cytotoxic activity of effector cells. We have found that the doxorubicin dose escalation up to 2 mg/kg doesn’t improve the antitumor effect of chemo-imunotherapy immunosuppressive but nevertheless has immunosuppressive effects. The obtained results indicate the feasibility of combining chemo- and immunotherapeutic methods for developing more effective approaches for the prevention of recurrence in patients with malignant neoplasms after primary treatment.
